Advertisement

p53: Oncogene, Tumor Suppressor, or Both?

  • W. Deppert
Conference paper

Abstract

Cytogenetic [34] and molecular genetic [25] analyses have identified tumor-specific genomic changes, thus providing accumulating evidence for a genetic component in the etiology of human cancer. Cancer results from multiple genetic lesions, induced by a variety of genotoxic agents. The ensuing mutations range from point mutations via deletions in a single gene up to chromosomal rearrangements. It can be expected that some of those mutations might activate genes that stimulate cell growth, while others might inactivate genes involved in negative regulation of cell growth. Until very recently cancer biologists in their overwhelming majority have focused on activated genes, i.e. the oncogenes. This, primarily, has experimental reasons. Oncogenes are mutant alleles of proto-oncogenes. Through their mutation they have acquired novel or aberrant properties that promote cell transformation. Oncogenes function in a genetically dominant manner and provide a selective growth advantage for cells expressing them, thus facilitating their identification [3, 4]. However, one has to be aware that genomic rearrangements are frequent events for mutations causally involved in the development of cancer, and are observed in virtually all tumor cells. One would expect that such large-scale genetic alterations will, with a higher frequency, result in elimination or inactivation rather than in activation of genes. Consequently, the inactivation of negatively regulating genes should comprise an important step in the development of cancer.

Keywords

Friend Virus Tumorigenic Phenotype Abelson Murine Leukemia Promote Cell Transformation GAL4 Fusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C (1991) Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083–1091PubMedCrossRefGoogle Scholar
  2. 2.
    Birchmeier W, Behrens J, Weidner KM, Frixen UH, Schipper J (1991) Dominant and recessive genes involved in tumor cell invasion. Curr Opin Cell Biol 3:832–840PubMedCrossRefGoogle Scholar
  3. 3.
    Bishop JM (1987) The molecular genetics of cancer. Science 235:305–311PubMedCrossRefGoogle Scholar
  4. 4.
    Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235–248PubMedCrossRefGoogle Scholar
  5. 5.
    Boyd JA, Barrett JC (1990) Tumor suppressor genes: possible functions in the negative regulation of cell proliferation. Mol Carcinog 3:325–329PubMedCrossRefGoogle Scholar
  6. 6.
    Caron de Fromentel C, Soussi T (1992) The TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes, Chromosome Cancer 4:1–15CrossRefGoogle Scholar
  7. 7.
    Chow V, Ben-David Y, Bernstein A, Benchimol S, Mowat M (1987) Multistage Friend erythroleukemia: independent origin of tumor clones with normal or rearranged p53 cellular oncogenes. J Virol 61:2777–2781PubMedGoogle Scholar
  8. 8.
    Crawford L (1983) The 53,000-dalton cellular protein and its role in transformation. Int Rev Exp Pathol 25:1–50PubMedGoogle Scholar
  9. 9.
    Deppert W (1989) P53: oncogene or anti-oncogene? A critical review. In: Lother H, Dernick R, Ostertag W (eds) Vectors as tools for the study of normal and abnormal growth and differentiation. Springer, Berlin Heidelberg New York, pp 399–406 (NATO ASI series, vol H34)CrossRefGoogle Scholar
  10. 10.
    Deppert W, Buschhausen-Denker G, Patschinsky T, Steinmeyer K (1990) Cell cycle control of p53 in normal (3T3) or chemically transformed (Meth A) mouse cells: II. Requirement for cell cycle progression. Oncogene 5:1701–1706PubMedGoogle Scholar
  11. 11.
    Eliyahu D, Goldfinger N, Pinhasi-Kimhi O, Shaulsky G, Skurnik Y, Arai N, Rotter V, Oren M (1988) Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3:313–321PubMedGoogle Scholar
  12. 12.
    Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86:8763–8767PubMedCrossRefGoogle Scholar
  13. 13.
    Fields S, Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049PubMedCrossRefGoogle Scholar
  14. 14.
    Finlay CA, Hinds PW, Levine A J (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093PubMedCrossRefGoogle Scholar
  15. 15.
    Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531–539PubMedGoogle Scholar
  16. 16.
    Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602Google Scholar
  17. 17.
    Green MR (1989) When the products of oncogenes and anti-oncogenes meet. Cell 56:1–3PubMedCrossRefGoogle Scholar
  18. 18.
    Herskowitz I (1987) Functional inactivation of genes by dominant negative mutations. Nature 329:219–222PubMedCrossRefGoogle Scholar
  19. 19.
    Hinds P, Finlay C, Levine AJ (1989) Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63: 739–746PubMedGoogle Scholar
  20. 20.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 Mutations in human cancers. Science 253:49–53PubMedCrossRefGoogle Scholar
  21. 21.
    Jenkins JR, Stiirzbecher H-W (1988) The p53 oncogene. In: Reddy EP, Skalka AM, Curran T (eds) The oncogene handbook. Elsevier, AmsterdamGoogle Scholar
  22. 22.
    Kaczmarek L, Oren M, Baserga R (1986) Co-operation between the p53 protein tumor antigen and platelet-poor plasma in the induction of cellular DNA synthesis. Exp Cell Res 162:268–272PubMedCrossRefGoogle Scholar
  23. 23.
    Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, Friedman P, Prives C, Vogelstein B (1991) Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 6:131–136PubMedGoogle Scholar
  24. 24.
    Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708–1711PubMedCrossRefGoogle Scholar
  25. 25.
    Klein G (1987) The approaching era of the tumor suppressor genes. Science 238:1539–1545PubMedCrossRefGoogle Scholar
  26. 26.
    Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261–263PubMedCrossRefGoogle Scholar
  27. 27.
    Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E et al. (1991) p53 Mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51:4090–4096PubMedGoogle Scholar
  28. 28.
    Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453–456PubMedCrossRefGoogle Scholar
  29. 29.
    Mercer WE, Avignolo C, Baserga R (1984) Role of p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol 4:276–281PubMedGoogle Scholar
  30. 30.
    Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ (1990) Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87: 6166–6170PubMedCrossRefGoogle Scholar
  31. 31.
    Michalovitz D, Halevy O, Oren M (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671–680PubMedCrossRefGoogle Scholar
  32. 32.
    Michalovitz D, Halevy O, Oren M (1991) p53 Mutations: gains or losses? J Cell Biochem 45:22–29PubMedCrossRefGoogle Scholar
  33. 33.
    Milner J, Medcalf EA (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765–774PubMedCrossRefGoogle Scholar
  34. 34.
    Mitelman F (1988) Catalog of chromosome aberrations in cancer. Liss, New YorkGoogle Scholar
  35. 35.
    Moran E (1991) Cycles within cycles. Curr Op Cell Biol 1:281–283Google Scholar
  36. 36.
    Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S (1985) Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 314:633–636PubMedCrossRefGoogle Scholar
  37. 37.
    Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK (1990) Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863–5867PubMedCrossRefGoogle Scholar
  38. 38.
    Munroe DG, Rovinski B, Bernstein A, Benchimol S (1988) Loss of a highly conserved domain on p53 as a result of gene deletion during Friend virus-induced erythroleukemia. Oncogene 2:621–624PubMedGoogle Scholar
  39. 39.
    Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708PubMedCrossRefGoogle Scholar
  40. 40.
    Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard TJW, Angus B, Hörne CHW (1991) p53 Expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164:75–81PubMedCrossRefGoogle Scholar
  41. 41.
    Raycroft L, Wu H, Lozano G (1990) Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049–1051PubMedCrossRefGoogle Scholar
  42. 42.
    Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, Lane DP (1990) p53 Mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555–7559PubMedCrossRefGoogle Scholar
  43. 43.
    Shohat O, Greenberg M, Reisman D, Oren M, Rotter V (1987) Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene 1:277–283PubMedGoogle Scholar
  44. 44.
    Soussi T, Caron de Fromentel C, May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945–952PubMedGoogle Scholar
  45. 45.
    Steinmeyer K, Deppert W (1988) DNA binding properties of murine p53. Oncogene 3:501–507PubMedGoogle Scholar
  46. 46.
    Weißker S, Müller B, Homfeld A, Deppert W. (1992) Specific and complex interactions of murine p53 with DNA. Oncogene 7:1921–1932PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • W. Deppert
    • 1
  1. 1.Heinrich-Pette-Institut für Experimentelle Virologie und ImmunologieUniversität HamburgHamburg 20Germany

Personalised recommendations